



Two Abstracts Presented at ASTRO 2018 Sunday October 21:

First Report of the Implantable Uni-Directional Planar LDR Brachytherapy for Patients with Locally Advanced Pancreatic Cancer

Widening the Therapeutic Window using an Implantable, Uni-directional LDR Brachytherapy Sheet as a Boost in Pancreatic Cancer

For Release at ASTRO 2018 From San Antonio, TX

RESEARCH TRIANGLE PARK, N.C.--CivaTech Oncology—

Early results are promising for a new radiation implant, the CivaSheet® used to treat resectable pancreatic cancer patients. While surgery has been the only curative option for these patients, there is still an 18%-40% risk of margin-positive resections reported in the literature which conveys high risks of local control and poor survival. CivaSheet® is a permanent LDR brachytherapy implant that incorporates gold shielding by directing radiation to positive surgical margins while protecting healthy tissues. CivaSheet was implanted in five pancreatic cancer patients in a 15 minute procedure. No device related post-operative complications were reported. There was no disease progression in the region irradiated by CivaSheet.

CivaSheet is capable of providing a localized radiation boost with a safe dose that is dramatically increased when compared to external beam capabilities. The shielding in the device protects the small bowel delivering about 1/10<sup>th</sup> the dose compared to a boost with external beam. These patient medical reports and their dosimetric study show that applying this uni-directional source to the area of highest risk can enhance the therapeutic index by improving local control and minimizing toxicities when treating pancreatic cancer. The possibilities for use in other disease sites are vast including pelvic re-irradiation, colorectal or gyn cancers, sarcomas, axillary disease and more.

Study sites for the 11,000-15,000 pancreatic cancer patients are found at:

[www.clinicaltrials.gov/ct2/show/NCT02843945](http://www.clinicaltrials.gov/ct2/show/NCT02843945) .

About CivaSheet®:

Designed and manufactured by [CivaTech Oncology](http://www.civattech.com), CivaSheet® is a flexible, implantable intra-operative radiation therapy device (brachytherapy) that emits unidirectional radiation by integrating gold shielding into its polymer encapsulation. CivaSheet has broad FDA clearance to include pancreatic cancer and many other malignancies. CivaSheet enables boost radiation therapy in patients who have otherwise received the maximum radiation dose.

Development of the CivaSheet and clinical studies are partially supported by the NIH, NCI and the NC Biotech Center.



About CivaTech® Oncology:

CivaTech Oncology's products bring meaningful improvements to provide targeted radiation therapy. For more information, please visit [www.civatechoncology.com](http://www.civatechoncology.com).

#### **ABOUT ASTRO**

*The American Society for Radiation Oncology (ASTRO) is the world's largest radiation oncology society, with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies. The Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes three medical journals, [International Journal of Radiation Oncology • Biology • Physics](#), [Practical Radiation Oncology](#) and [Advances in Radiation Oncology](#); developed and maintains an extensive patient website, [RT Answers](#); and created the nonprofit foundation [Radiation Oncology Institute](#). To learn more about ASTRO, visit [astro.org](http://astro.org) or [RTanswers.org](http://RTanswers.org), sign up to [receive our news](#) and follow us on our [blog](#), [Facebook](#) and [Twitter](#).*

#### **Safe Harbor Statement**

Our communication may include predictions, estimates or other information that might be considered forward-looking. While these statements represent our current judgement, they are subject to risks and uncertainties that could cause actual results to differ. This news release contains additional and/or updated information from the study author(s).

Copyright © 2018 CivaTech Oncology®, All rights reserved.

CIVATECH ONCOLOGY

#### **Release Summary**

Team of expert physicians at VCU, including Emma Fields MD, conclude: Applying CivaSheet during surgery to the area at highest risk of recurrence can enhance the therapeutic index by improving local control and minimizing toxicities in pancreatic cancer patients.

#### **Contacts**

CivaTech Oncology Inc.®  
Randy Harrison, 919-314-5515  
National Sales Manager  
[rharrison@civatechoncology.com](mailto:rharrison@civatechoncology.com)